This article is more than 5 years old. Information may no longer be current.

Eylea approved in Europe for visual impairment due to myopic choroidal neovascularization

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Eylea has received approval in Europe for the treatment of visual impairment secondary to myopic choroidal neovascularization, Regeneron announced in a press release.

Eylea (aflibercept) is currently approved in Europe for the treatment of patients with neovascular age-related macular degeneration, visual impairment due to diabetic macular edema and visual impairment due to macular edema secondary to retinal vein occlusion.

Regeneron has exclusive rights to Eylea in the U.S., while Bayer Healthcare has exclusive marketing rights outside of the U.S.